US Patent Issued to ANTENGENE THERAPEUTICS on Sept. 23 for "Ectonucleotidase inhibitors and methods of use thereof" (California Inventors)

ALEXANDRIA, Va., Sept. 23 -- United States Patent no. 12,421,273, issued on Sept. 23, was assigned to ANTENGENE THERAPEUTICS Ltd. (Hong Kong).

"Ectonucleotidase inhibitors and methods of use thereof" was invented by Lijing Chen (Cupertino, Calif.), Roland Joseph Billedeau (Santa Clara, Calif.) and Jim Li (San Francisco).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention."

The patent was filed on Nov. 1, 2023, under Application No. 18/499,248.

*For further information, including images, char...